{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:09Z","timestamp":1790689749997,"version":"4.1.0"},"reference-count":49,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:p>BACKGROUND. Pompe disease is a lysosomal storage disorder that leads to the accumulation of glycogen and subsequently to muscle weakness, organ damage, and death. Pompe disease is detectable through newborn screening, and treatment has become available recently.<\/jats:p>\n               <jats:p>OBJECTIVE. Our goal was to review systematically all available evidence regarding screening for infantile Pompe disease to help policy makers determine whether Pompe disease should be added to their state's newborn screening battery.<\/jats:p>\n               <jats:p>METHODS. We searched online databases, including Medline, clinicaltrials.gov, and the Computer Retrieval of Information on Scientific Projects database, as well as Web sites maintained by federal organizations (eg, the Food and Drug Administration) and other nonprofit or private organizations (eg, the March of Dimes and Genzyme Corp), by using the terms \u201cglycogen storage disease type II,\u201d \u201cPompe disease,\u201d and \u201cPompe's disease.\u201d We also obtained preliminary findings from a screening program in Taiwan. Data were critically appraised and extracted by 2 investigators, one who is an expert in systematic review methods and the other who is an expert in Pompe disease.<\/jats:p>\n               <jats:p>RESULTS. The prevalence of Pompe disease has been estimated to be \u223c1 case per 40000. Small studies suggest that enzyme therapy is highly efficacious in infantile Pompe disease and that earlier intervention leads to improved outcomes. Screening cannot distinguish between infantile and late-onset Pompe disease. The current screening program in Taiwan has a high false-positive rate; however, the threshold was purposely set low to ensure that no case would be missed.<\/jats:p>\n               <jats:p>CONCLUSIONS. Pilot studies of screening are needed to identify the most efficacious strategy for screening and determine how to manage cases of late-onset Pompe disease before screening for Pompe disease is adopted widely by newborn screening programs.<\/jats:p>","DOI":"10.1542\/peds.2007-0388","type":"journal-article","created":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T17:08:45Z","timestamp":1193936925000},"page":"e1327-e1334","source":"Crossref","is-referenced-by-count":53,"title":["Newborn Screening for Pompe Disease: Synthesis of the Evidence and Development of Screening Recommendations"],"prefix":"10.1542","volume":"120","author":[{"given":"Alex R.","family":"Kemper","sequence":"first","affiliation":[{"name":"Program on Pediatric Health Services Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Department of Pediatrics, National Taiwan University College of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Lloyd-Puryear","sequence":"additional","affiliation":[{"name":"Genetic Services Branch, Division of Services for Children With Special Health Care Needs, Maternal and Child Health Bureau, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"key":"2022051612041068700_R1","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med.\u20082006;8:267\u2013288","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"2022051612041068700_R2","unstructured":"US Food and Drug Administration. FDA news: FDA approves first treatment for Pompe disease. Available at: www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01365.html. Accessed February 7, 2007"},{"key":"2022051612041068700_R3","unstructured":"Agency for Healthcare Research and Quality. Methods and background: US Preventive Services Task Force (USPSTF). Available at: www.ahrq.gov\/clinic\/uspstmeth.htm#Methods. Accessed February 7, 2007"},{"key":"2022051612041068700_R4","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology.\u20082007;68:99\u2013109","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"2022051612041068700_R5","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr.\u20082006;148:671\u2013676","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"2022051612041068700_R6","doi-asserted-by":"crossref","unstructured":"van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics.\u20082003;112:332\u2013340","DOI":"10.1542\/peds.112.2.332"},{"key":"2022051612041068700_R7","doi-asserted-by":"crossref","unstructured":"Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med.\u20082001;3:132\u2013138","DOI":"10.1097\/00125817-200103000-00008"},{"key":"2022051612041068700_R8","doi-asserted-by":"crossref","unstructured":"Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr.\u20082000;137:283\u2013285","DOI":"10.1067\/mpd.2000.107112"},{"key":"2022051612041068700_R9","doi-asserted-by":"crossref","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA.\u20081999;281:249\u2013294","DOI":"10.1001\/jama.281.3.249"},{"key":"2022051612041068700_R10","doi-asserted-by":"crossref","unstructured":"Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet.\u20082004;12:87\u201392","DOI":"10.1038\/sj.ejhg.5201044"},{"key":"2022051612041068700_R11","doi-asserted-by":"crossref","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet.\u20081999;105:151\u2013156","DOI":"10.1007\/s004399900075"},{"key":"2022051612041068700_R12","doi-asserted-by":"crossref","unstructured":"D'Ancona GG, Wurm J, Croce CM. Genetics of type II glycogenosis: assignment of the human gene for acid \u03b1-glucosidase to chromosome 17. Proc Natl Acad Sci USA.\u20081979;76:4526\u20134529","DOI":"10.1073\/pnas.76.9.4526"},{"key":"2022051612041068700_R13","doi-asserted-by":"crossref","unstructured":"Hermans MMP, van Leenen D, Kroos MA, et al. Twenty-two novel mutations in the lysosomal \u03b1-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat.\u20082004;23:47\u201356","DOI":"10.1002\/humu.10286"},{"key":"2022051612041068700_R14","doi-asserted-by":"crossref","unstructured":"Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet.\u20081999;7:713\u2013716","DOI":"10.1038\/sj.ejhg.5200367"},{"key":"2022051612041068700_R15","doi-asserted-by":"crossref","unstructured":"Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet.\u20081998;79:69\u201372","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K"},{"key":"2022051612041068700_R16","doi-asserted-by":"crossref","unstructured":"An Y, Young SP, Kishnani PS, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab.\u20082005;85:247\u2013254","DOI":"10.1016\/j.ymgme.2005.03.010"},{"key":"2022051612041068700_R17","doi-asserted-by":"crossref","unstructured":"Chester MA, Lundblad A, Hager A, et al. Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III. Lancet.\u20081983;1(8331):994\u2013995","DOI":"10.1016\/S0140-6736(83)92122-0"},{"key":"2022051612041068700_R18","unstructured":"Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001"},{"key":"2022051612041068700_R19","doi-asserted-by":"crossref","unstructured":"Ing RJ, Cook DR, Bengur RA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth.\u20082004;14:514\u2013519","DOI":"10.1111\/j.1460-9592.2004.01242.x"},{"key":"2022051612041068700_R20","doi-asserted-by":"crossref","unstructured":"Jack RM, Gordon C, Scott CR, Kishnani PS, Bali D. The use of acarbose inhibition in the measurement of acid \u03b1-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease. Genet Med.\u20082006;8:307\u2013312","DOI":"10.1097\/01.gim.0000217785.19262.9e"},{"key":"2022051612041068700_R21","doi-asserted-by":"crossref","unstructured":"Okumiya T, Keulemans JLM, Kroos MA, et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab.\u20082006;88:22\u201328","DOI":"10.1016\/j.ymgme.2005.10.016"},{"key":"2022051612041068700_R22","doi-asserted-by":"crossref","unstructured":"Zhang H, Kallwass H, Young SP, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid \u03b1-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med.\u20082006;8:302\u2013306","DOI":"10.1097\/01.gim.0000217781.66786.9b"},{"key":"2022051612041068700_R23","doi-asserted-by":"crossref","unstructured":"Bembi B, Ciana G, Martini C, et al. Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II. J Inherit Metab Dis.\u20082003;26:675\u2013681","DOI":"10.1023\/B:BOLI.0000005618.76542.ed"},{"key":"2022051612041068700_R24","doi-asserted-by":"crossref","unstructured":"Bodamer OA, Haas D, Hermans MM, Reuser AJ, Hoffmann GF. l-Alanine supplementation in late infantile glycogen storage disease type II. Pediatr Neurol.\u20082002;27:145\u2013146","DOI":"10.1016\/S0887-8994(02)00413-7"},{"key":"2022051612041068700_R25","doi-asserted-by":"crossref","unstructured":"Bodamer OA, Halliday D, Leonard JV. The effects of l-alanine supplementation in late-onset glycogen storage disease type II. Neurology.\u20082000;55:710\u2013712","DOI":"10.1212\/WNL.55.5.710"},{"key":"2022051612041068700_R26","doi-asserted-by":"crossref","unstructured":"Umpleby AM, Wiles CM, Trend PS, et al. Protein turnover in acid maltase deficiency before and after treatment with a high protein diet. J Neurol Neurosurg Psychiatry.\u20081987;50:587\u2013592","DOI":"10.1136\/jnnp.50.5.587"},{"key":"2022051612041068700_R27","unstructured":"Harris RE, Hannon D, Vogler C, Hug G. Bone marrow transplantation in type IIa glycogen storage disease. Birth Defects Orig Artic Ser.\u20081986;22:119\u2013132"},{"key":"2022051612041068700_R28","doi-asserted-by":"crossref","unstructured":"Watson JG, Gardner-Medwin D, Goldfinch ME, Pearson AD. Bone marrow transplantation for glycogen storage disease type II (Pompe's disease). N Engl J Med.\u20081986;314:385","DOI":"10.1056\/NEJM198602063140611"},{"key":"2022051612041068700_R29","doi-asserted-by":"crossref","unstructured":"Mobarhan S, Pintozzi RL, Damle P, Friedman H. Treatment of acid maltase deficiency with a diet high in branched-chain amino acids. JPEN J Parenter Enteral Nutr.\u20081990;14:210\u2013212","DOI":"10.1177\/0148607190014002210"},{"key":"2022051612041068700_R30","doi-asserted-by":"crossref","unstructured":"Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human \u03b1-glucosidase from rabbit milk in Pompe patients. Lancet.\u20082000;356:397\u2013398","DOI":"10.1016\/S0140-6736(00)02533-2"},{"key":"2022051612041068700_R31","unstructured":"Micromedex: Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Micromedex; 2007. Accessed February 7, 2007"},{"key":"2022051612041068700_R32","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease. J Pediatr.\u20082006;149:89\u201397","DOI":"10.1016\/j.jpeds.2006.02.035"},{"key":"2022051612041068700_R33","doi-asserted-by":"crossref","unstructured":"Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid \u03b1-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord.\u20082005;15:24\u201331","DOI":"10.1016\/j.nmd.2004.10.009"},{"key":"2022051612041068700_R34","doi-asserted-by":"crossref","unstructured":"Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study. Neuropediatrics.\u20082005;36:6\u201311","DOI":"10.1055\/s-2005-837543"},{"key":"2022051612041068700_R35","doi-asserted-by":"crossref","unstructured":"Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al. Long-term intravenous treatment of Pompe disease with recombinant human \u03b1-glucosidase from milk. Pediatrics.\u20082004;113(5). Available at: www.pediatrics.org\/cgi\/content\/full\/113\/5\/e448.","DOI":"10.1542\/peds.113.5.e448"},{"key":"2022051612041068700_R36","doi-asserted-by":"crossref","unstructured":"Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating \u03b1-glucosidase replacement therapy for Pompe disease. Pediatrics.\u20082004;114(4). Available at: www.pediatrics.org\/cgi\/content\/full\/114\/4\/e532.","DOI":"10.1542\/peds.2003-0988-L"},{"key":"2022051612041068700_R37","doi-asserted-by":"crossref","unstructured":"Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta.\u20082004;347:97\u2013102","DOI":"10.1016\/j.cccn.2004.04.009"},{"key":"2022051612041068700_R38","doi-asserted-by":"crossref","unstructured":"Li Y, Scott CR, Chamoles NA, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem.\u20082004;50:1785\u20131796","DOI":"10.1373\/clinchem.2004.035907"},{"key":"2022051612041068700_R39","doi-asserted-by":"crossref","unstructured":"Niizawa G, Levin C, Aranda C, Blanco M, Chamoles NA. Retrospective diagnosis of glycogen storage disease type II by use of a newborn-screening card. Clin Chim Acta.\u20082005;359:205\u2013206","DOI":"10.1016\/j.cccn.2005.04.007"},{"key":"2022051612041068700_R40","doi-asserted-by":"crossref","unstructured":"Umapathysivam K, Whittle AM, Ranieri E, et al. Determination of acid \u03b1-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem.\u20082000;46:1318\u20131325","DOI":"10.1093\/clinchem\/46.9.1318"},{"key":"2022051612041068700_R41","doi-asserted-by":"crossref","unstructured":"Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab.\u20082006;88:307\u2013314","DOI":"10.1016\/j.ymgme.2006.02.013"},{"key":"2022051612041068700_R42","doi-asserted-by":"crossref","unstructured":"Bailey DB, Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev.\u20082006;12:270\u2013279","DOI":"10.1002\/mrdd.20119"},{"key":"2022051612041068700_R43","doi-asserted-by":"crossref","unstructured":"Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA.\u20082003;290:2564\u20132572","DOI":"10.1001\/jama.290.19.2564"},{"key":"2022051612041068700_R44","doi-asserted-by":"crossref","unstructured":"American College of Medical Genetics, Newborn Screening Expert Group. Toward a uniform screening panel and system: executive summary. Pediatrics.\u20082006;117(5 pt 2):S296\u2013S307","DOI":"10.1542\/peds.2005-2633I"},{"key":"2022051612041068700_R45","unstructured":"Genzyme Corp. Pompe registry. Available at: www.lsdregistry.net\/pomperegistry\/hcp\/understd\/reg\/preg_hc_u_aboutreg.asp. Accessed February 7, 2007"},{"key":"2022051612041068700_R46","doi-asserted-by":"crossref","unstructured":"Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics.\u20082006;117:1793\u20131799","DOI":"10.1542\/peds.2005-2547"},{"key":"2022051612041068700_R47","doi-asserted-by":"crossref","unstructured":"Waisbren SE. Newborn screening for metabolic disorders. JAMA.\u20082006;296:993\u2013995","DOI":"10.1001\/jama.296.8.993"},{"key":"2022051612041068700_R48","unstructured":"Agency for Healthcare Research and Quality. Task force ratings. Available at: www.ahrq.gov\/clinic\/3rduspstf\/ratings.htm. Accessed February 7, 2007"},{"key":"2022051612041068700_R49","doi-asserted-by":"crossref","unstructured":"Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy.\u20082005;4:239\u2013247","DOI":"10.2165\/00148365-200504040-00006"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/5\/e1327\/1031246\/zpe011070e1327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/5\/e1327\/1031246\/zpe011070e1327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T12:05:15Z","timestamp":1652702715000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/5\/e1327\/71071\/Newborn-Screening-for-Pompe-Disease-Synthesis-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,11,1]]},"published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0388","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}